FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the Uni…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet The consensus price target hints at a 67% upside potential for Foghorn Therapeutics (FHTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | ||
 Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out. | ||
 Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | ||
 Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||